4-Chloro-N-(4-{2,4-diamino-6-[(benzyloxy)methyl]pyrimidin-5-yl}phenyl)benzamide | 848665-98-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Chloro-N-(4-{2,4-diamino-6-[(benzyloxy)methyl]pyrimidin-5-yl}phenyl)benzamide
• 英文别名: 4-chloro-N-[4-(2,4-diamino-6-benzyloxymethyl-pyrimidin-5-yl)-phenyl]-benzamide；4-chloro-N-[4-[2,4-diamino-6-(phenylmethoxymethyl)pyrimidin-5-yl]phenyl]benzamide
• CAS: 848665-98-5
• 化学式: C₂₅H₂₂ClN₅O₂
• 分子量: 459.935
• InChiKey: HMVBVORAUABLNG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  116
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-(4-amino-phenyl)-6-benzyloxymethyl-pyrimidine-2,4-diamine 、 对氯苯甲酸 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 2.08h， 以35%的产率得到4-Chloro-N-(4-{2,4-diamino-6-[(benzyloxy)methyl]pyrimidin-5-yl}phenyl)benzamide
  参考文献：
  名称：

  Pyrimidine derivatives as ghrelin receptor modulators

  摘要：

  本发明涉及式(I)的化合物，或者其治疗上适宜的盐或前药，该化合物的制备、含有该化合物的组合物以及在预防或治疗由生长激素释放素调节的疾病中使用该化合物，包括厌食症、癌症恶病质、进食障碍、与年龄相关的身体组成下降、体重增加、肥胖和糖尿病。

  公开号：

  US20050070712A1

文献信息

• TREAMENT FOR CHEMICAL SUBSTANCE ADDICTION
  申请人：Dickson Suzanne L.

  公开号：US20100093638A1

  公开（公告）日：2010-04-15

  The present invention provides a method for the treatment of chemical substance abuse by selectively inhibiting ghrelin activity in humans comprising administering to a human in need thereof a therapeutically-effective amount of a ghrelin receptor ligand (GHS-RL). The ghrelin receptor ligand (GHS-RL) can be selected from the group consisting of a ghrelin receptor antagonist (GHS-RA), a ghrelin receptor inverse agonist (GHS-RIA), and a ghrelin receptor partial agonist (GHS-RPA). More specifically, the invention provides a method for treating alcohol related disorders in humans comprising administering to a human in need thereof a therapeutically-effective amount of a compound which is a ghrelin receptor ligand (GHS-RL), such as a ghrelin receptor antagonist (GHS-RA), a ghrelin receptor inverse agonist (GHS-RIA) and a ghrelin receptor partial agonist (GHS-RPA).

  本发明提供了一种治疗人类化学物质滥用的方法，该方法通过选择性抑制人体中的胃饥饿素活性，包括向需要治疗的人类中投与治疗有效量的胃饥饿素受体配体（GHS-RL）。胃饥饿素受体配体（GHS-RL）可以从以下组中选择，包括胃饥饿素受体拮抗剂（GHS-RA）、胃饥饿素受体逆激动剂（GHS-RIA）和胃饥饿素受体部分激动剂（GHS-RPA）。更具体地，本发明提供了一种治疗人类酒精相关障碍的方法，包括向需要治疗的人类中投与治疗有效量的化合物，该化合物是胃饥饿素受体配体（GHS-RL），例如胃饥饿素受体拮抗剂（GHS-RA）、胃饥饿素受体逆激动剂（GHS-RIA）和胃饥饿素受体部分激动剂（GHS-RPA）。
• Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists
  申请人：Xin Zhili

  公开号：US20050171132A1

  公开（公告）日：2005-08-04

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the action of ghrelin receptor, including Prader-Willi syndrome, eating disorder, weight gain, weight-loss maintainance following diet and exercise, obesity and disorders associated with obesity such as non-insulin dependent diabetes mellitus.

  本发明涉及式（I）的化合物，或其治疗上适宜的盐或前药，以及该化合物的制备、含有该化合物的组合物以及在预防或治疗由胃饥饿素受体调节的疾病中使用该化合物，包括普拉德-威利综合症、进食障碍、体重增加、饮食和运动后体重减轻维持、肥胖症以及与肥胖症相关的疾病，如非胰岛素依赖性糖尿病。
• NEW TREATMENT FOR CHEMICAL SUBSTANCE ADDICTION
  申请人：Dickson, Suzanne L

  公开号：EP2155227A1

  公开（公告）日：2010-02-24
• [EN] DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS<br/>[FR] DERIVES DE DIAMINOPYRIMIDINE UTILISES COMME ANTAGONISTES SELECTIFS DU RECEPTEUR DES SECRETAGOGUES DE L'HORMONE DE CROISSANCE (GHS-R)
  申请人：ABBOTT LAB

  公开号：WO2005030734A1

  公开（公告）日：2005-04-07

  The present invention is related to compounds of formula (I), (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the action of ghrelin receptor, including Prader-Willi syndrome, eating disorder, weight gain, weight-loss maintainance following diet and exercise, obesity and disorders associated with obesity such as non-insulin dependent diabetes mellitus.
• [EN] NEW TREATMENT FOR CHEMICAL SUBSTANCE ADDICTION<br/>[FR] NOUVEAU TRAITEMENT POUR UNE DÉPENDANCE À UNE SUBSTANCE CHIMIQUE
  申请人：DICKSON SUZANNE L

  公开号：WO2009020419A1

  公开（公告）日：2009-02-12

  The present invention provides a method for the treatment of chemical substance abuse by selectively inhibiting ghrelin activity in humans comprising administering to a human in need thereof a therapeutically-effective amount of a ghrelin receptor ligand (GHS-RL). The ghrelin receptor ligand (GHS-RL) can be selected from the group consisting of a ghrelin receptor antagonist (GHS-RA), a ghrelin receptor inverse agonist (GHS-RIA), and a ghrelin receptor partial agonist (GHS-RPA). More specifically, the invention provides a method for treating alcohol related disorders in humans comprising administering to a human in need thereof a therapeutically-effective amount of a compound which is a ghrelin receptor ligand (GHS-RL), such as a ghrelin receptor antagonist (GHS-RA), a ghrelin receptor inverse agonist (GHS-RIA) and a ghrelin receptor partial agonist (GHS-RPA).